Amneal posts Q2 non-GAAP EPS of $0.30 and revenue of $796M, exceeding expectations and raising full-year outlook.
Amneal Pharmaceuticals reported second-quarter non-GAAP earnings per share of $0.30, beating estimates by $0.07. Revenue reached $796M, a 9.8% year-over-year increase, surpassing expectations by $25.09M.
The company’s adjusted EBITDA rose 12% to $206 million compared to the same period in 2025. Strong performance in generics and specialty segments drove the results, prompting an upward revision of its full-year 2026 outlook.
Shares may react positively to the earnings beat and improved guidance, though market response will depend on broader sector trends.